德谷胰岛素与甘精胰岛素在2型糖尿病中的疗效与安全性
DEVOTE研究为双盲、治疗达标、事件驱动的非劣效性心血管结局试验,纳入7637例2型糖尿病患者,随机接受每日一次德谷胰岛素(3818例)或甘精胰岛素U100(3819例)。主要复合心血管结局在德谷组8.5%、甘精组9.3%(HR 0.91,95%CI 0.78-1.06;非劣效P<0.001)。24个月时两组糖化血红蛋白均值均为7.5±1.2%,德谷组空腹血糖更低(128±56 vs 136±57 mg/dL,P<0.001)。预设的严重低血糖在德谷组4.9%、甘精组6.6%(绝对差1.7个百分点;率比0.60,优效性P<0.001;比值比0.73,优效性P<0.001)。
要点
- 心血管高危2型糖尿病患者中,德谷胰岛素主要心血管事件非劣于甘精胰岛素U100(HR 0.91,95%CI 0.78-1.06;非劣效P<0.001)。
- 德谷组严重低血糖4.9% vs 甘精组6.6%,绝对差1.7个百分点(率比0.60,优效性P<0.001)。
- 24个月时两组糖化血红蛋白均值均为7.5±1.2%,德谷组空腹血糖显著更低(128±56 vs 136±57 mg/dL,P<0.001)。
- 两组不良事件发生率无差异。
- 随机人群中85.2%(6509例)有确诊心血管疾病、慢性肾脏病或两者兼有。
适用人群与场景
- 2型糖尿病患者,随机纳入7637例;其中6509例(85.2%)有确诊心血管疾病、慢性肾脏病或两者兼有。
- 基线平均年龄65.0岁,平均糖尿病病程16.4年,平均糖化血红蛋白8.4±1.7%,83.9%的患者正在使用胰岛素。
处置流程与药物剂量
- 德谷胰岛素或甘精胰岛素U100每日一次,于晚餐至睡前之间给药,治疗达标设计。
研究设计与关键结果
- 双盲、治疗达标、事件驱动的非劣效性心血管结局试验,纳入7637例2型糖尿病患者,随机分为德谷胰岛素组(3818例)和甘精胰岛素U100组(3819例)。
- 主要复合结局(心血管原因死亡、非致死性心肌梗死或非致死性卒中的首次发生)在德谷组325例(8.5%)、甘精组356例(9.3%),HR 0.91(95%CI 0.78-1.06),非劣效性P<0.001,预设非劣效界值为1.3。
- 24个月时平均糖化血红蛋白两组均为7.5±1.2%;平均空腹血糖德谷组128±56 mg/dL vs 甘精组136±57 mg/dL,德谷组显著更低(P<0.001)。
- 预设的经裁定的严重低血糖(按美国糖尿病协会定义)在德谷组187例(4.9%)、甘精组252例(6.6%),绝对差1.7个百分点;率比0.60(优效性P<0.001),比值比0.73(优效性P<0.001)。
- 两组不良事件发生率无差异。
证据类型、等级与局限
- 证据类型:双盲、随机、治疗达标、事件驱动的非劣效性心血管结局试验。
- 试验由诺和诺德等资助;DEVOTE试验注册号NCT01959529。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对心血管高危的2型糖尿病患者,德谷胰岛素每日一次的心血管安全性非劣于甘精胰岛素U100。
- 与甘精胰岛素U100相比,德谷胰岛素可降低经裁定的严重低血糖发生率(4.9% vs 6.6%)。
- 两组不良事件发生率无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.
METHODS: We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted secondary outcome.
RESULTS: Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups.
CONCLUSIONS: Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events. (Funded by Novo Nordisk and others; DEVOTE ClinicalTrials.gov number, NCT01959529 .).
参考来源
- Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017. PMID: 28605603. doi:10.1056/NEJMoa1615692
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。